Literature DB >> 28419670

Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.

Anna Solini1, Chiara Rossi2, Chiara M Mazzanti3, Agnese Proietti1, Hermann Koepsell4, Ele Ferrannini5.   

Abstract

AIM: To quantify the expression of sodium-glucose co-transporter (SGLT)2 and SGLT1, their cognate basolateral transporters, GLUT2 and GLUT1, and the transcriptional regulator of SGLTs in renal tissue obtained from people with T2DM and a group of well-matched people without diabetes.
METHODS: We measured SGLT2 and SGLT1 expression in unaffected renal tissue from 19 people with T2DM and 20 people without diabetes, matched for age and estimated glomerular filtration rate (controls), undergoing unilateral nephrectomy. Expression of SGLT2 and SGLT1, as well as that of GLUT2 and GLUT1, was quantified using real-time and digital PCR; an affinity-purified antibody against human SGLT2 was used to localize SGLT2 by immunohistochemistry.
RESULTS: SGLT2 expression was higher in control than T2DM tissue (median [interquartile range] target/β-actin 1.62 [2.02] vs 0.67 [0.61]; P < .0001), and SGLT1 trended in the same direction (0.98 [1.19] vs 0.44 [0.48]; P = .08). Immunohistochemistry clearly localized SGLT2 to the tubular brush-border membranes, and was semi-quantitatively stronger in control than T2DM tissue (5.0 [1.0] vs 4.0 [1.0] score units; P = .043). GLUT2 (control vs T2DM: 1.00 [0.69] vs 0.49 [0.36]) and GLUT1 expression (control vs T2DM: 0.86 [0.73] vs 0.35 [0.30]; P = .0007 for both) were closely correlated with those of the respective SGLT partner. Hypoxia-inducible factor 1α, more abundant in control than T2DM tissue, might be a transcription factor involved in the modulation of SGLT2 expression.
CONCLUSIONS: In whole renal tissue, expressions of SGLT2/GLUT2 and SGLT1/GLUT1 are coupled and slightly lower in typical people with T2DM as compared with well-matched people without diabetes.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  SGLT2 inhibitor; clinical physiology; type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28419670     DOI: 10.1111/dom.12970

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  24 in total

Review 1.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

2.  Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.

Authors:  Harindra Rajasekeran; Heather N Reich; Michelle A Hladunewich; Daniel Cattran; Julie A Lovshin; Yuliya Lytvyn; Petter Bjornstad; Vesta Lai; Josephine Tse; Leslie Cham; Syamantak Majumder; Bridgit B Bowskill; M Golam Kabir; Suzanne L Advani; Ian W Gibson; Manish M Sood; Andrew Advani; David Z I Cherney
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-15

Review 3.  The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.

Authors:  Hadi Fattah; Volker Vallon
Journal:  Drugs       Date:  2018-05       Impact factor: 9.546

4.  What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.

Authors:  Jessica A Dominguez Rieg; Timo Rieg
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

5.  Renal SGLT mRNA expression in human health and disease: a study in two cohorts.

Authors:  Vikas Srinivasan Sridhar; Jaya Prakash N Ambinathan; Matthias Kretzler; Laura L Pyle; Petter Bjornstad; Sean Eddy; David Z Cherney; Heather N Reich
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-23

Review 6.  Glucose transporters in the kidney in health and disease.

Authors:  Volker Vallon
Journal:  Pflugers Arch       Date:  2020-03-06       Impact factor: 3.657

Review 7.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

Review 8.  Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences.

Authors:  Jessica A Dominguez Rieg; Jianxiang Xue; Timo Rieg
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-09       Impact factor: 2.894

Review 9.  SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.

Authors:  Alexia Piperidou; Charalampos Loutradis; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2020-08-10       Impact factor: 3.012

10.  Acquired Decline in Ultrafiltration in Peritoneal Dialysis: The Role of Glucose.

Authors:  Raymond T Krediet
Journal:  J Am Soc Nephrol       Date:  2021-07-28       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.